New study reveals common lipid binding sites as immunobots target therapeutic targets for cancer
Of the millions of newly diagnosed new cancer patients in the U.S.
each year, approximately 30% are diagnosed with non-small cell lung cancer.
Approved in advance of implementation by drug companies in response to regulatory and regulatory requests, the work represents a significant advance not only in immunotherapy, but potentially therapeutic approaches to treat non-small cell lung cancer.
The research was conducted by Thannickalasmaannii (Thanx), a member of the HaloHelix Consortium, a large group of synthetic, single cell and antigenic molecules from Xenobio Research, Inc.
and a corporate research and development affiliate of Sansomon Philanthropies, Inc.